Photo of Dr Ke Xu

Dr Ke Xu

Telephone:

Email:

Location:

  • University College Hospital Grafton Way Building
  • University College Hospital Macmillan Cancer Centre

GMC/GDC number:

7006599

Professional background

Dr Xu is a consultant haematologist specialising in diagnostic haematology, myeloma, and leukaemia. She completed her Doctorate of Medicine in 2004.

Between 2005 and 2009, she was appointed a postdoc research associate at NYU Hospital for Joint Diseases, Duke University Medical Center, and Imperial College London. She completed her postgraduate medical training in general medicine in various London hospitals and haematology training at Royal Marsden and St. George's Hospital.

She was awarded MRCP in 2013 and FRCPath in 2018.

Specialties

Research interests

  • Myeloma bone disease
  • Diagnostic haematology

Languages spoken

Mandarin

Publications

  • Xu K, Abusalim E, Vitsaras E, Orfinada K, Baker R, Nachweva E, Wilson A, O’Nions J, Gupta R. Diagnosis and treatment of T/myeloid mixed -phenotype acute leukaemia (T/M-MPAL). eJHaem. 10/January/2025. e1075. DOI: 10.1002/jha2.1075
  • Xu K, Agbuduwe C, Kanellias N, Wilson W, McMillan A, Papanikolaou X, Lee L, Popat R, Sive J, Rabin N, Yong K, Parcharidou A, Kyriakou C. Bone-independent extramedullary disease is associated with inferior overall survival in multiple myeloma patients: a single center, real-world experience. Haematologica. 5/December/2024. DOI:10.3324/haematol.2024.286409
  • Cashman H, Wilson AJ, Xu K, Nacheva E, Baker R, Gupta R. Untangling the clonal architecture in a case of acute myeloid leukaemia with multiple cytogenetically unrelated clones. Clinical Hematology International. 12/November/2024; 6(4):100-103. DOI: 10.46989/001c.124931
  • Mullanfiroze K, Jones C, Williams D, Vieira M, Wechalekar A, Papanikolaou X, Popat R, Kyriakou C, Xu K. Management of multiple myeloma presented as malignant spinal cord compression during pregnancy: a case report. Clinical Hematology International. 23/October/2024; 6(4): 89-92. DOI: 10.46989/001c.124664
  • Xu K, Vitsaras E, Gupta R. Chronic myeloid leukaemia (CML) in T-lymphoblastic blast crisis with near early T cell progenitor (ETP) immunophenotype. International Journal of Laboratory Hematology. 11/October/2024.DOI:10.1111/IJLH.14383
  • Xu K, Kaffo E, Baker R, Nacheva E, McMillan A, Lee L, Papanikolaou X, Popat R, Sive J, Yong K, Rabin N, Kyriakou C, Gupta R. Myeloid neoplasm post cytotoxic treatment in patients with myeloma. eJHaem. 30/September/2024; 5(5): 1089-1091. DOI： 10.1002/jha2.1017
  • Melotti D, Asher S, Troy-Barnes E, Nesr G, Wilson W, Camilleri M, Popat R, Xu K, Rabin N, Sive J, Papanikalaou X, Lee L, McMillan A, Yong K, Sive J, Kyriakou C. Outcomes of Melphalan 140 mg/m2 followed by autologous stem cell transplantation in multiple myeloma patients with co-morbidities: single centre experience. eJHaem. 19/August/2024; 5(5): 1102-1106. DOI:10.1002/jha2.977
  • Xu K, Nacheva E. Acute Myeloid Leukemia with NUP98::NSD1 fusion. Hematopathology. 22/July/2024; 9(1):11-12. ISSN: 2379-822X
  • Buck C, Castillo FB, Bettio E, Land J, McCourt O, Poole H, Tarling R, Yong K, Popat R, Lee L, McMillan A, Papanikolaou X, Xu K, Kyriakou C, Rabin K, Wechalekar A, Fisher A, Sive J. The impact of continuous lenalidomide maintenance treatment on people living with Multiple Myeloma – a single-centre, qualitative evaluation study. Supportive care in cancer. 2/July/2024; 32: 479. DOI:10.1007/s00520-024-08663-4
  • Xu K, Gupta S, Kaffo E, Baker R, Nacheva E, O’Nions J, Wilson AJ, Gupta R. The use of targeted ribonucleic acid (RNA)-sequencing assay in the diagnostic evaluation of acute myeloid leukaemia (AML). Journal of hematopathology. 25/June/2024. DOI:10.1007/s12308-024-00594-7
  • Xu K, Maharaj C. VEXAS syndrome. Hematopathology. 15/May/2024; 9(1):9-10. ISSN: 2379-822X
  • Xu K, Nacheva E. Secondary plasma cell leukaemia with plasmablastic morphology. Journal of hematopathology. 6/April/2024:17(1) DOI:10.1007/s12308-024-00583-w
  • Xu K, Kyriakou C. Extramedullary myeloma progressed to plasmablastic myeloma. Clinical Hematology International, 12/January/2024: 6(1): 13-15. DOI: 10.46989/001c.92050
  • Xu K, Nacheva E. Acute Myeloid Leukaemia (AML) with KMT2A rearrangement presented with haemophagocytic lymphohistiocytosis (HLH). International Journal of Laboratory Haematology, April/2024: 46 (2): 214-215. DOI: 10.1111/ijlh.14183
  • Xu K, Childerhouse A, Gupta R. Mast cell leukaemia progressed from MDS after acquiring KIT mutation. International Journal of Laboratory Haematology, April/2024: 46 (2): 212-213. DOI: doi.org/10.1111/ijlh.14174.
  • Tayabali S, Baker R, Nacheva E, O’Nions J, Gupta R, Wilson A, Xu K. The use of Q-fusion gene screening assay (Q30) in the diagnostic evaluation of acute myeloid leukaemia (AML). Journal of Hematopathology. March/2024: 17 (1): 37-39. DOI: 10.1007/s12308-023-00571-6
  • Xu K, Nacheva E. Chronic myeloid leukaemia (CML) presenting in B-lymphoblastic crisis- a diagnostic challenge. Journal of Hematopathology, December/2023; 16(4): 243-245. DOI: 10.1007/s12308-023-00560-9
  • Xu K. Microgranular acute promyelocytic leukaemia (APML) with FLT3 p.N676K. Clinical hematology and research. ISSN:2689-8896. 18/June/2023; 6(1): 82-83. DOI: 10.36959/831/392
  • Asher S, Shah R, Ings S, Horder J, Newrick F, Marfil J, Kesse Adu R, Streetly M, Trompeter S, Lee L, Wisniowski B, Mahmood S, Xu K, Papanikalaou X, McMillan A, Popat R, Yong K, Sive J, Kyriakou C, Rabin N. Haemopoietic stem cell mobilisation followed by high-dose chemotherapy and autologous stem cell transplantation for patients with sickle cell disease and myeloma. BJH, 2023; 202:1224-1227 doi: 10.1111/bjh.18990.
  • Nesr G, Shah R, Kyriakou C, Sive J, Popat R, Yong K, Wisniowski B, Xu K, Wechalekar A, Lee L, Ings S, Papanikolaou X, Mahmood S, McMillan A, Horder J, Newrick F, Marfil J, Ainley L, Asher S, Cheesman S, Rabin N. Impact of timing of stem cell return following high dose melphalan in multiple myeloma patients with renal impairment: a single centre experience. Leukemia and lymphoma. 1/June/2023; 64 (8): 1465-1471. https://doi.org/10.1080/10428194.2023.2216817
  • Xu K. Sulfasalazine induced myeloid maturation arrest. Hematopathology. 2023; 8(1): 10. May/2023.ISSN: 2379-822X
  • Asher S, Kazantzi A, Dekaj F, Steventon L, Khatun A, Rabin N, Wechalekar A, Sive J, Kyriakou C, Papanikolaou X, Xu K, Mahmood S, Wisniowski B, Lee L, Yong K, Popat R. Under-representation of ethnic minorities in early phase clinical trials for multiple myeloma. Haematologica. 2022 December; 107: 2961-2965. https://doi.org/10.3324/haematol.2022.281322kxu0000
  • Howells L, Chan WY, Horder J, Newrick F, Marfi J, Sanchez E, Macmillan A, Wisniowski B, Mahmood S, Papanikolaou X, Lee L, Wechalekar A, Popat R, Sive J, Kyriakou C, Xu K, Nastouli E, Yong K, Rabin N. Patients with plasma cell disorders undergoing autologous stem cell transplant retain their humoral response to COVID-19 vaccination but falling titres emphasise the importance of re-vaccination. Leukemia and lymphoma. 2022 October; 63(10): 2489-2493.
  • Camilleri M, Bekris G, Sidhu G, Buck C, Elsden E, McCourt O, Horder J, Newrick F, LeCat C, Sive J, Papanikolaou X, Popat R, Lee L, Xu K, Kyriakou C, Rabin N, Yong K, Fisher A. The Impact of COVID-19 on Autologous Stem Cell Transplantation in Multiple Myeloma A single-centre service evaluation. Supportive care in cancer. 2022 September; 30(9):7469-7479
  • Xu K, Kamuriwo L, Anderson C, Jasani P. IgG kappa multiple myeloma with isolated central nervous system relapse. eJHaem. 2022 Aug; 3(3): 1082-1083.
  • Xu K, Childerhouse A, Gupta R. Burkitt leukaemia with B cell precursor immunophenotype. eJHaem. 2022 Aug; 3(3): 1044-1045.
  • Xu K, Nacheva E. Secondary AML with MLL gene amplification. Blood. 2022 July;140 (2): 161.
  • Chan WY, Howells L, Wilson W, Sanchez E, Ainley L, Chavda S, Dowling E, Correia N, Lecat C, Wisniowski B, Mahmood S, Papanikolaou X, Lee L, Sive J, Kyriakou C, Wechalekar A, Popat R, Rabin N, Nastouli E, Yong K, Xu K. Serological response to the BNT162b2 mRNA or ChAdOx-nCoV-19 vaccination after first and second doses in plasma cell disorder patients: influence of host and disease factors. BJH. 2022 Feb;196(3): e21-e26.
  • Xu K, Childerhouse A, Al-Hassani A, Kyriakou C. Plasmablastic myeloma progressed to plasma cell leukaemia. eJHaem. 2021 Nov; 2(4):869-870.
  • Chan WY, Sanchez E, Chavda S, Lecat C, Ainley L, Xu K, Wisniowski B, Mahmood S, Papanikolaou X, Kyriakou C, Sive J, Wechalekar A, Popat R, Rabin N, Lee L, Nastouli E, Yong K. Development of antibody response to SARS-CoV-2 following asymptomatic infection in patients with multiple myeloma on immunomodulatory therapy. BJH.  2021 Sep; 194(5):857-861
  • Chan WY, Macdonald C, Keenan A, Xu K, Bain BJ, Chiodini P. Severe babesiosis due to Babesia divergens acquired in the United Kingdom. American Journal of Hematology. 2021 July; 96(7):889-890
  • Ersek A, Xu K, Antonopoulos A, Butters TD, Santo AE, Vattakuzhi Y, Williams LM, Goudevenou K, Danks L, Freidin A, Spanoudakis E, Parry S, Papaioannou M, Hatjiharissi E, Chaidos A, Alonzi DS, Twigg G, Hu M, Dwek RA, Haslam SM, Roberts I, Dell A, Rahemtulla A, Horwood NJ, Karadimitris A. Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease. Journal of Clinical Investigation. 2015 Jun; 125(6): 2279-92.
  • Hu M, Bassett JH, Danks L, Howell PG, Xu K, Spanoudakis E, Kotsianidis I, Boyde A, Williams GR, Horwood N, Roberts IA, Karadimitris A. Activated Invariant NKT Cells Regulate Osteoclast Development and Function. J Immunol. 2011 Mar 1;186(5):2910-7.
  • Song H, Wei M, Xu K, Li X. Differential effect of three mitogen-activated protein kinases on lipoprotein (a)-induced human mesangial cell proliferation. Chinese Medical Journal 2010; 123 (2), 216-220
  • Zennadi R, Chien A, Xu K, Batchvarova M, Telen MJ. Sickle Red Cells Induce Adhesion of Naïve Lymphocytes and Monocytes to Endothelium. Blood. 2008 Oct 15;112(8):3474-83.
  • Zennadi R, De Castro L, Eyler C, Xu K, Ko M, Telen MJ. Role and Regulation of Sickle Red Cell Interactions with Other Cells: ICAM-4 and Other Adhesion Receptors. Transfusion Clinique et Biologique, 2008 Feb-Mar; 15(1-2):23-28.
  • Zennadi, R., Moeller, B.J., Whalen, E.J., Batchvarova, M., Xu, K., Shan, S.Q., Delahunty, M., Dewhirst, M.W., Telen, M.J.. Epinephrine-Induced Activation of LW-mediated Sickle Cell Adhesion and Vaso-occlusion In Vivo. Blood, 2007 Oct 1; 110(7): 2708-17.
  • Sun, A.Q., Balasubramaniyan, N., Xu, K., Liu, C.J., Ponamgi, V., Liu, H., Suchy, F.. Protein-Protein Interaction and Membrane Localization of Human Organic Solute Transporter (hOST). AJP-GI, 2007 Jun; 292(6): G1586-93.
  • Luan, Y., Yu X.P., Xu, K., Ding, B., Yu, J., Huang, Y., Yang, N., Lengyel, P., Di Cesare, P.E., Liu, C.. The retinoblastoma protein is an essential mediator of osteogenesis that links the p204 protein to the Cbfa1 transcription factor thereby increasing its activity. JBC, 2007 June 8; 282(23): 16860-70.
  • Liu, C.J., Zhang, Y., Xu, K., Parsons, D., Alfonso, D., Di Cesare, P.E.. Transcriptional activation of cartilage oligomeric matrix protein by Sox9, Sox5, and Sox6 transcription factors and CBP/p300 coactivators. Frontiers in Bioscience, May 1, 2007; 12: 3899-3910.
  • Xu, K., Zhang, Y., Ilalov, K., Carlson, C., Feng, J., Di Cesare, P.E., Liu, C.. COMP Associate with GEP and Potentiates GEP-Stimulated Chondrocyte Proliferation. JBC, 2007 April 13; 282(15):11347-55. 
  • Liu, C.J., Kong, W., Xu, K., Luan, Y., Ilalov, K., Sehgal, B., Yu, S., Howell, R.D., Di Cesare, P.E.. ADAMTS-12 Associates with and Degrades Cartilage Oligomeric Matrix Protein. JBC, 2006 Jun 9;281(23):15800-8.
  • Liu, C.J., Kong, W., Ilalov, K., Yu, S., Xu, K., Prazak, L., Fajardo, M., Sehgal B., and Di Cesare, P.E. ADAMTS-7: A Novel Metalloproteinase that Directly Binds to and Degrades Cartilage Oligomeric Matrix Protein. FASEB Journal, 2006 May;20(7):988-90.